Fig. 2: Effect of ibudilast on heavy drinking days. | Translational Psychiatry

Fig. 2: Effect of ibudilast on heavy drinking days.

From: Ibudilast, a neuroimmune modulator, reduces heavy drinking and alcohol cue-elicited neural activation: a randomized trial

Fig. 2

Ibudilast reduced heavy drinking across time as compared to placebo, controlling for baseline heavy drinking and smoking status. Baseline percent heavy drinking is indicated as Day 0 for each medication group. Heavy drinking is presented as predicted probability of heavy drinking for each day per medication condition in the micro-longitudinal study. The shaded regions are the 95% confidence intervals surrounding each prediction.

Back to article page